Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin L Sos

Showing results (41-50 of 60) with videos related to

Pageof 6
Sort By:
NPJ Precision Oncology|December 18, 2021
Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancerDiana Schaufler, David F Ast, Hannah L Tumbrink, et al.
Nature Communications|August 4, 2019
MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancerMarcel A Dammert, Johannes Brägelmann, Rachelle R Olsen, et al.
Cancer Medicine|May 22, 2020
Sorafenib and everolimus in patients with advanced solid tumors and KRAS-mutated NSCLC: A phase I trial with early pharmacodynamic FDG-PET assessmentLucia Nogova, Christian Mattonet, Matthias Scheffler, et al.
Cell Reports|September 21, 2017
Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline CarcinomaJohannes Brägelmann, Marcel A Dammert, Felix Dietlein, et al.
Cancer Cell|January 17, 2017
MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase InhibitionGurkan Mollaoglu, Matthew R Guthrie, Stefanie Böhm, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 24, 2015
Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer PatientsKatharina König, Martin Peifer, Jana Fassunke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2016
Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR InhibitorsSandra Ortiz-Cuaran, Matthias Scheffler, Dennis Plenker, et al.
Science Translational Medicine|June 16, 2017
Drugging the catalytically inactive state of RET kinase in RET-rearranged tumorsDennis Plenker, Maximilian Riedel, Johannes Brägelmann, et al.
Nature Communications|September 18, 2021
MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-IJohannes Brägelmann, Carina Lorenz, Sven Borchmann, et al.
Nature|October 23, 2009
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1David A Barbie, Pablo Tamayo, Jesse S Boehm, et al.
Pageof 6

Showing results (41-50 of 60) with videos related to

Sort By:
Pageof 6
NPJ Precision Oncology|December 18, 2021
Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancerDiana Schaufler, David F Ast, Hannah L Tumbrink, et al.
Nature Communications|August 4, 2019
MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancerMarcel A Dammert, Johannes Brägelmann, Rachelle R Olsen, et al.
Cancer Medicine|May 22, 2020
Sorafenib and everolimus in patients with advanced solid tumors and KRAS-mutated NSCLC: A phase I trial with early pharmacodynamic FDG-PET assessmentLucia Nogova, Christian Mattonet, Matthias Scheffler, et al.
Cell Reports|September 21, 2017
Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline CarcinomaJohannes Brägelmann, Marcel A Dammert, Felix Dietlein, et al.
Cancer Cell|January 17, 2017
MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase InhibitionGurkan Mollaoglu, Matthew R Guthrie, Stefanie Böhm, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 24, 2015
Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer PatientsKatharina König, Martin Peifer, Jana Fassunke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2016
Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR InhibitorsSandra Ortiz-Cuaran, Matthias Scheffler, Dennis Plenker, et al.
Science Translational Medicine|June 16, 2017
Drugging the catalytically inactive state of RET kinase in RET-rearranged tumorsDennis Plenker, Maximilian Riedel, Johannes Brägelmann, et al.
Nature Communications|September 18, 2021
MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-IJohannes Brägelmann, Carina Lorenz, Sven Borchmann, et al.
Nature|October 23, 2009
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1David A Barbie, Pablo Tamayo, Jesse S Boehm, et al.
Pageof 6